Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

This study has been completed.
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Aventis Pharmaceuticals
Information provided by:
Dana-Farber Cancer Institute Identifier:
First received: September 9, 2005
Last updated: April 24, 2009
Last verified: April 2009